Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › MA › Needham › NPI 1750705885
NP / PA

Cox, Sara

Cox, Sara was paid $19K by Medicaid between Jan 2018 and May 2018, across 4 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 37% of everything it billed.

33Billing provider infoCOX, SARA
NEEDHAM, MA 02494
33aNPI1750705885assigned 02/10/2014
28Total paid$19K
24GClaims319
24DCodes billed4
24AFirst – last monthJan 2018 – May 2018
Compared with peers

Next to other Family Nurse Practitioner providers in Massachusetts

Rank by total paid#94 of 327
Median peer was paid$5K
This provider vs. median3.5×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$2.5K$5.0K$7.5K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2018319$19K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 37% 88 45 $7K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 36% 140 79 $7K
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 14% 51 28 $3K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 13% 40 27 $2K

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.